Tsuji Kyodo Update 2018

Today, Follicum announced their phase 2a trial of FOL-005 for the scalp is fully recruited. The trial consists of injections of Follicum’s modified peptide, FOL-005, over a three month period. This trial design is supportive for a data readout by year’s end, as enrollment has been completed while still in June. CEO of Follicum, Jan…